OncoMatch/Clinical Trials/NCT07886229
Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer
Official title: A Prospective, Multicenter, Open-Label Study of Propranolol Hydrochloride in Combination With Toripalimab and Platinum-Based Chemotherapy as Perioperative Treatment for Resectable Non-Small Cell Lung Cancer
Is NCT07886229 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1 trial studies multiple treatments including Propranolol Hydrochloride and Toripalimab for resectable non-small-cell lung cancer.
Treatment: Propranolol Hydrochloride · Toripalimab · Chemotherapy — This is a prospective, multicenter, open-label study designed to evaluate the safety and tolerability of propranolol hydrochloride in combination with toripalimab and platinum-based chemotherapy as perioperative treatment in patients with resectable non-small cell lung cancer (NSCLC). Propranolol hydrochloride is a beta- adrenergic blocking agent which is associated with augment of immune cell responses. Propranolol hydrochloride may improve the responses of immune checkpoint inhibitors in treating patients with resectable NSCLC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Required: ROS1 wild-type
Disease stage
Required: Stage II, IIIB
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: anti-PD-1 therapy
Prior exposure to any anti-PD-1 ... antibody therapy
Cannot have received: anti-PD-L1 therapy
Prior exposure to any ... anti-PD-L1 ... antibody therapy
Cannot have received: anti-PD-L2 therapy
Prior exposure to any ... anti-PD-L2 ... antibody therapy
Cannot have received: anti-CTLA-4 therapy
Prior exposure to any ... CTLA-4 antibody therapy
Cannot have received: CD137 antibody therapy
Prior exposure to any ... CD137 ... antibody therapy
Cannot have received: T-cell co-stimulation or checkpoint pathway inhibitor
any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Cannot have received: systemic anti-tumor therapy
No previous anti-tumor treatment
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 × 10^9/L; Platelet count ≥ 100 × 10^9/L; Hemoglobin ≥ 9.0 g/dL (no blood transfusion or erythropoietin-dependent administration within 7 days)
Kidney function
Serum creatinine ≤ 1.5 × ULN or Cr clearance rate ≥ 60 mL/min (Cockcroft-Gault formula); urine protein (UPRO) < 2+ or 24-hour urine protein quantification < 1 g
Liver function
Total bilirubin (TBIL) ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN (≤ 5 × ULN with liver metastasis); No liver metastasis
Cardiac function
NYHA classification < 3; Left ventricular ejection fraction ≥ 50%; Baseline ECG shows no PR interval prolongation or atrioventricular block
Meet the following laboratory indicators (14 days before the first treatment): ... Blood routine: Absolute neutrophil count ≥ 1.5 × 10^9/L; Platelet count ≥ 100 × 10^9/L; Hemoglobin content ≥ 9.0 g/dL (no blood transfusion or no erythropoietin-dependent administration within 7 days). ... Liver function: Total bilirubin (TBIL) ≤ 1.5 × ULN; No liver metastasis; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN. For patients with liver metastasis, ALT or AST ≤ 5 × ULN. ... Kidney function: Serum creatinine (Cr) ≤ 1.5 × ULN or Cr clearance rate ≥ 60 mL/min (Cockcroft-Gault formula), and urine routine test shows urine protein (UPRO) < 2+ or 24-hour urine protein quantification < 1 g. ... Coagulation function: Within 7 days before the study treatment, INR ≤ 1.5 × ULN or PT ≤ 1.5 × ULN; if the subject is receiving anticoagulation treatment, as long as the PT is within the range of the anticoagulant drug, it is acceptable; ... Cardiac function: NYHA classification < 3; Left ventricular ejection fraction ≥ 50%; Baseline electrocardiogram shows no PR interval prolongation or atrioventricular block
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07886229 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
Does this trial require ROS1?
Yes, ROS1 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or IIIB is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages